The CAPS Screen: 10 Fit Health-Care Stocks

Recs

6

In 2006, the United States spent about $2.1 trillion on health care. With an aging population that's increasing in number, and escalating costs of medical care and technology, that figure is expected to grow 6.7% annually to reach $4.3 trillion in 2017.

With that in mind, I used our new CAPS screening tool to find out which health-care stocks the CAPS investing community is the most bullish on.

These stocks also have:

  • Market caps greater than $1 billion.
  • Five-star ratings, the highest possible, from our CAPS community.

Remember, in the first year for which we have data, five-star companies outperformed with an average gain of nearly 28%.

Company

Share Price

Market Cap
(in billions)

Amedisys

$52.41

$1.4

China Medical (Nasdaq: CMED)

$39.30

$1.1

Genzyme (Nasdaq: GENZ)

$68.43

$18.3

Gilead Sciences (Nasdaq: GILD)

$53.87

$49.7

Hologic (Nasdaq: HOLX)

$22.09

$5.6

Johnson & Johnson

$66.15

$186.4

Meridian Bioscience

$29.28

$1.2

Mindray Medical (NYSE: MR)

$37.63

$4.0

Stryker (NYSE: SYK)

$62.30

$25.7

Teva Pharmaceutical (Nasdaq: TEVA)

$45.93

$35.6

Data from Motley Fool CAPS and Yahoo! Finance as of May 20.

Of course, true Fools know that it takes more than a screen to generate healthy returns. Come and join us on Motley Fool CAPS, where the collective wisdom of our 105,000-strong CAPS community can help you make your investment decisions.

If you’re looking for more investment ideas, try our Rule Breakers growth-stock newsletter. You can read all our past recommendations, including our favorite opportunities in health care and medicine, free for 30 days, with no obligation.

For more Foolish content:

“The Next Great Investment”… That’s how a top global investor describes India’s potential. On Nov. 28, The Motley Fool’s Tim Hanson returns to India to prove it. Follow along in real time and get his TOP pick first (Hanson returned from China in July with a stock that’s up 169%!). Enter email below.

Ilan Moscovitz doesn’t own any of the companies mentioned in this article. Mindray Medical is a Motley Fool Rule Breakers selection. Johnson & Johnson is an Income Investor pick. Amedysis is a Stock Advisor selection. The Fool has a disclosure policy.

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

TD AMERITRADE
more info
ShareBuilder
more info
Power E*Trade

more info
Scottrade
more info
Fool Disclosure

DocumentId: 649731, ~/Articles/ArticleHandler.aspx, 11/24/2009 6:45:08 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

The Must-Read Story on Fool.com
Why Investors Should Be Excited for a Bank Breakup

Related Tickers

11/23/2009 4:00 PM
HOLX $14.28 Down -0.11 -0.76%
Hologic, Inc. CAPS Rating: *****
MR $29.14 Up +0.25 +0.87%
Mindray Medical In… CAPS Rating: *****
GENZ $50.24 Up +0.19 +0.38%
Genzyme Corp CAPS Rating: ****
GILD $47.01 Up +0.62 +1.34%
Gilead Sciences, I… CAPS Rating: *****
CMED $12.67 Up +0.09 +0.72%
China Medical Tech… CAPS Rating: *****
TEVA $53.43 Up +0.71 +1.35%
Teva Pharmaceutica… CAPS Rating: *****
SYK $49.52 Up +0.79 +1.62%
Stryker Corp CAPS Rating: *****

Community: Investing Wiki

Term Of The Hour

Creative destruction: Creative destruction is the theory that suggest economies are strengthened by new companies that destroy or diminish existing companies.

Want to learn more or edit this definition?
Click here to read more!